News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
BioSpace News Archive
Browse BioSpace’s published news and press releases by year, month, and day.
311 Results
Year
2005 (24679)
2006 (34770)
2007 (39687)
2008 (39410)
2009 (42118)
2010 (39616)
2011 (38383)
2012 (38416)
2013 (36268)
2014 (39673)
2015 (44433)
2016 (38330)
2017 (37191)
2018 (39124)
2019 (51338)
2020 (57666)
2021 (58724)
2022 (53928)
2023 (42568)
2024 (38486)
2025 (18801)
Month
January (2883)
February (2030)
March (1769)
April (2200)
May (2664)
June (3162)
July (3087)
August (3801)
September (4260)
October (5136)
November (4629)
December (3503)
Day
1 (335)
2 (311)
3 (237)
4 (70)
6 (2)
7 (48)
8 (54)
9 (56)
10 (84)
11 (40)
13 (1)
14 (80)
15 (90)
16 (78)
17 (59)
18 (31)
20 (1)
21 (91)
22 (78)
23 (75)
24 (68)
25 (25)
26 (1)
28 (4)
29 (222)
30 (262)
31 (261)
Year
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Month
January
February
March
April
May
June
July
August
September
October
November
December
Day
1
2
3
4
6
7
8
9
10
11
13
14
15
16
17
18
20
21
22
23
24
25
26
28
29
30
31
Pharm Country
KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira™ (phentermine hydrochloride USP) 8 mg Tablets, CIV
KVK Tech, Inc. announced the LOMAIRA 1-2-3 program.
May 2, 2018
·
5 min read
Business
IONTAS and aTen Therapeutics Announce Collaboration to Discover Therapeutic Oncology Leads
IONTAS Limited and Ten Therapeutics Limitedannounced that they have entered into a strategic collaboration.
May 2, 2018
·
2 min read
BioCapital
LYCRA® Brand Celebrates 60 Years of Groundbreaking Innovations
INVISTA is celebrating the 60th anniversary of LYCRA® fiber with a donation to the National Inventors Hall of Fame.
May 2, 2018
·
2 min read
Nobles Medical Launches Sales of its NobleStitch™ EL for PFO Closure in Spain
NMT2 announces the further expansion of the NobleStitch™ EL with the addition of Hospitals in Barcelona.
May 2, 2018
·
5 min read
Policy
/R E P E A T -- Notice to the media - Technical Briefing to provide an update on the Government of Canada’s latest actions in response to the opioid crisis/
Health Canada will publish final regulations in Canada Gazette, Part II
May 2, 2018
·
1 min read
Business
European Medical Tourism & Global Healthcare Congress Generates New Business from the Middle East, GCC, Russia & CIS
The European Medical Tourism & Global Healthcare Congress closes up its agenda and convenes in Athens in just two weeks.
May 2, 2018
·
5 min read
BioMidwest
United Therapeutics Corporation Reports First Quarter 2018 Financial Results
United Therapeutics Corporation announced its financial results for the first quarter ended March 31, 2018.
May 2, 2018
·
21 min read
Business
Aroa Biosurgery and Hydrofera Team up in US
Aroa Biosurgery and United States medical products company Hydrofera are launching Appulse in North America.
May 2, 2018
·
2 min read
Deals
Janssen to Acquire BeneVir Biopharm to Advance Immunotherapy Regimens
Janssen Biotech, Inc. announced that it has entered into a definitive agreement under which it will acquire BeneVir Biopharm, Inc. (BeneVir), a privately-held, biopharmaceutical company specializing in the development of oncolytic immunotherapies.
May 2, 2018
·
5 min read
Policy
Realm Therapeutics Files Registration Statement with the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares
Realm Therapeutics plc announces it has confidentially submitted a registration statement to the United States Securities and Exchange Commission (SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company’s ordinary shares on the Nasdaq Global Market (Nasdaq).
May 2, 2018
·
4 min read
Previous
27 of 32
Next